J
Judith Trotman
Researcher at Concord Repatriation General Hospital
Publications - 206
Citations - 6543
Judith Trotman is an academic researcher from Concord Repatriation General Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 29, co-authored 145 publications receiving 4377 citations. Previous affiliations of Judith Trotman include Royal Prince Alfred Hospital & Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington,N. George Mikhaeel,Lale Kostakoglu,Michel Meignan,Martin Hutchings,Stefan P. Müeller,Lawrence H. Schwartz,Emanuele Zucca,Richard I. Fisher,Judith Trotman,Otto S. Hoekstra,Rodney J. Hicks,Michael O'Doherty,Roland Hustinx,Alberto Biggi,Bruce D. Cheson +15 more
TL;DR: This article comprises the consensus reached to update guidance on the use of PET-CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice and late-phase trials.
Journal ArticleDOI
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
Peter Johnson,Massimo Federico,Amy A Kirkwood,Alexander Fosså,Leanne Berkahn,Angelo Michele Carella,Francesco d'Amore,Gunilla Enblad,Antonella Franceschetto,Michael J. Fulham,Stefano Luminari,Michael O'Doherty,Pip Patrick,Thomas Roberts,Gamal Sidra,L. Stevens,Paul Smith,Judith Trotman,Z. Viney,John Radford,Sally F. Barrington +20 more
TL;DR: Although the results fall just short of the specified noninferiority margin, the omission of bleomycin from the ABVD regimen after negative findings on interim PET resulted in a lower incidence of pulmonary toxic effects than with continued ABVD but not significantly lower efficacy.
Journal ArticleDOI
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince,H. Miles Prince,Youn H. Kim,Steven M. Horwitz,Reinhard Dummer,Julia Scarisbrick,Pietro Quaglino,Pier Luigi Zinzani,Pascal Wolter,Jose A Sanches,Pablo L. Ortiz-Romero,Oleg E. Akilov,Larisa J. Geskin,Larisa J. Geskin,Judith Trotman,Kerry Taylor,Stéphane Dalle,Michael Weichenthal,Jan Walewski,David E. Fisher,Brigitte Dréno,Rudolf Stadler,Tatyana Feldman,Timothy M. Kuzel,Yinghui Wang,Maria Corinna Palanca-Wessels,Erin Zagadailov,William L. Trepicchio,Wenwen Zhang,H. Lin,Yi Liu,Dirk Huebner,Meredith Little,Sean Whittaker,Madeleine Duvic,David Joske,Ian D. Lewis,Constanze Jonak,Franz Trautinger,Oliver Bechter,Dominique Bron,Vladmir Cláudio Cordeiro de Lima,José Antonio Sanches,Richard Klasa,Martine Bagot,Marie Beylot-Barry,Michel D'Incan,Florent Grange,Jan P. Nicolay,Marion Wobser,Chalid Assaf,Carmen Loquai,Michele Spina,Alberto Bosi,Pier Paolo Fattori,Aleksandra Grzanka,Andres Lopez-Hernandez,Jose Juan Rifon Roca,Silvana Novelli Canales,Timothy M Illidge,Rod Johnson,Stephen Morris,Pam McKay,O. Akilov,Steve Horwitz,Barbara Pro,Timothy Kuzel,Adam Lerner,Herbert Eradat,Lubomir Sokol,David C. Fisher,Sarah Hughey +71 more
TL;DR: Significant improvement in objective response lasting at least 4 months was seen with brentuximab vedotin versus physician's choice of methotrexate or bexarotene in previously treated patients with CD30-positive cutaneous T-cell lymphomas.
Journal ArticleDOI
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
Meletios A. Dimopoulos,Alessandra Tedeschi,Judith Trotman,Ramón García-Sanz,David MacDonald,Véronique Leblond,Beatrice Mahe,Charles Herbaux,Constantine S. Tam,Lorella Orsucci,M. Lia Palomba,Jeffrey Matous,Chaim Shustik,Efstathios Kastritis,Steven P. Treon,Jianling Li,Zeena Salman,Thorsten Graef,Christian Buske +18 more
TL;DR: Among patients with Waldenström's macroglobulinemia, theUse of ibrutinib–rituximab resulted in significantly higher rates of progression‐free survival than the use of placebo–ritUXimab, both among those who had received no previous treatment and among those with disease recurrence.
Journal ArticleDOI
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Constantine S. Tam,Stephen Opat,Shirley D'Sa,Wojciech Jurczak,Hui Peng Lee,Gavin Cull,Gavin Cull,Roger G. Owen,Paula Marlton,Paula Marlton,Björn E. Wahlin,Ramón García Sanz,Helen McCarthy,Stephen P. Mulligan,Alessandra Tedeschi,Jorge J. Castillo,Jarosław Czyż,Carlos Fernández de Larrea,David Belada,Edward N. Libby,Jeffrey Matous,Marina Motta,Tanya Siddiqi,Monica Tani,Marek Trneny,Monique C. Minnema,Christian Buske,Veronique Leblond,Judith Trotman,Judith Trotman,Wai Y. Chan,Jingjing Schneider,Sunhee Ro,Aileen Cohen,Jane Huang,Meletios A. Dimopoulos +35 more
TL;DR: Zanubrutinib treatment was associated with a trend toward better response quality and less toxicity, particularly cardiovascular toxicity, which demonstrate that zanubRutinIB and ibrut inib are highly effective in the treatment of WM.